The invention relates to the stereoisomers of 4-4-[(S/R)-5-[(((aryl)methylene)- amino)methyl]-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-ones described by the chemical formulae (S)-(9) and (R)-(9). The optical isomer of compound (9) with the (S)- configuration is industrially applicable for the manufacture of the antithrombotic drug rivaroxaban (1). The new preparation process of rivaroxaban comprises a reaction of (S)-1- chloro-3-(((aryl)methylene)amino)propan-2-ols (S)-(14) with alkyl 4-(3-oxomorpholine-4- yl)phenylcarbamates (15) providing the key intermediate (S)-(9), which is further subjected to hydrolytic deprotection and subsequent acylation, producing rivaroxaban. The commercially available (S)-epichlorohydrin has been conveniently used as the chiral building block for the production of the key intermediate.
该发明涉及4-4-[(S/R)-5-[(((芳基)亚甲基)
氨基)甲基]-2-氧代-1,3-
噁唑烷-3-基]苯基}
吗啡啶-3-酮的立体异构体,
化学式分别为(S)-(9)和(R)-(9)。化合物(9)的光学异构体,具有(S)-构型,可用于工业制造抗凝血药
利伐沙班(1)。
利伐沙班的新制备过程包括(S)-1-
氯-3-(((芳基)亚甲基)
氨基)
丙烷-2-醇(S)-(14)与烷基4-(3-氧代
吗啡啶-4-基)苯基
氨甲酸酯(15)发生反应,得到关键中间体(S)-(9),随后经
水解去保护和酰化反应,制备
利伐沙班。商业上可获得的(S)-
环氧氯丙烷已方便地用作生产关键中间体的手性构建块。